Literature DB >> 15748096

Treatment of Legionnaires' disease.

Guy W Amsden1.   

Abstract

Legionnaires' disease is pneumonia, usually caused by Legionella pneumophila, which can range in severity from mild to quite severe. While it is commonly acquired in the community, it can just as easily be acquired nosocomially from water sources that have not been appropriately decontaminated. While historically initial treatment was always with erythromycin, current case series and treatment recommendations suggest that outpatients receive immediate treatment with one of the following antibacterials: azithromycin, erythromycin, clarithromycin, telithromycin, doxycycline or an extended-spectrum fluoroquinolone. If the symptoms are severe enough to warrant hospitalisation then the patient should receive treatment with parenteral azithromycin or extended-spectrum fluoroquinolones followed by step-down to oral formulations to complete the regimens. While a shorter course of 7-10 days for more severe infections may be possible for intravenous/oral azithromycin, other antibacterials should be administered for a total of 10-21 days and started as soon as possible upon presentation to optimise outcomes.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15748096     DOI: 10.2165/00003495-200565050-00003

Source DB:  PubMed          Journal:  Drugs        ISSN: 0012-6667            Impact factor:   9.546


  36 in total

Review 1.  The treatment of Legionnaires' disease.

Authors:  M Dedicoat; P Venkatesan
Journal:  J Antimicrob Chemother       Date:  1999-06       Impact factor: 5.790

2.  Bactericidal effects of amoxycillin/clavulanic acid against a Legionella pneumophila pneumonia in the weanling rat.

Authors:  G M Smith; K H Abbott; M J Wilkinson; A S Beale; R Sutherland
Journal:  J Antimicrob Chemother       Date:  1991-01       Impact factor: 5.790

3.  Intravenous azithromycin as salvage therapy in a patient with Legionnaire's disease.

Authors:  L Dorrell; B Fulton; E L Ong
Journal:  Thorax       Date:  1994-06       Impact factor: 9.139

4.  In vitro activity of gemifloxacin (SB-265805, LB20304a) against Legionella pneumophila and its pharmacokinetics in guinea pigs with L. pneumophila pneumonia.

Authors:  P H Edelstein; T Shinzato; E Doyle; M A Edelstein
Journal:  Antimicrob Agents Chemother       Date:  2001-08       Impact factor: 5.191

Review 5.  Legionnaires' disease: a rational approach to therapy.

Authors:  Jorge Roig; Jordi Rello
Journal:  J Antimicrob Chemother       Date:  2003-03-28       Impact factor: 5.790

6.  Severe pneumonia due to Legionella pneumophila: prognostic factors, impact of delayed appropriate antimicrobial therapy.

Authors:  A Gacouin; Y Le Tulzo; S Lavoue; C Camus; J Hoff; R Bassen; C Arvieux; C Heurtin; R Thomas
Journal:  Intensive Care Med       Date:  2002-04-20       Impact factor: 17.440

7.  Bactericidal effects of co-amoxiclav (amoxycillin clavulanic acid) against a Legionella pneumophila pneumonia in the immunocompromised weanling rat.

Authors:  G M Smith; K H Abbott; R Sutherland
Journal:  J Antimicrob Chemother       Date:  1992-10       Impact factor: 5.790

8.  1974 outbreak of Legionnaires' Disease diagnosed in 1977. Clinical and epidemiological features.

Authors:  W Terranova; M L Cohen; D W Fraser
Journal:  Lancet       Date:  1978-07-15       Impact factor: 79.321

9.  The safety and efficacy of clarithromycin in patients with Legionella pneumonia.

Authors:  P Hamedani; J Ali; S Hafeez; R Bachand; G Dawood; S Quereshi; R Raza; Z Yab
Journal:  Chest       Date:  1991-12       Impact factor: 9.410

10.  Legionnaires' disease at a Dutch flower show: prognostic factors and impact of therapy.

Authors:  Kamilla D Lettinga; Annelies Verbon; Gerrit-Jan Weverling; Joop F P Schellekens; Jeroen W Den Boer; Ed P F Yzerman; Jacobus Prins; Wim G Boersma; Ruud J van Ketel; Jan M Prins; Peter Speelman
Journal:  Emerg Infect Dis       Date:  2002-12       Impact factor: 6.883

View more
  7 in total

1.  Legionellosis must be kept in mind in case of pneumonia with lung abscesses in children receiving therapeutic steroids.

Authors:  S Heine; A Fuchs; L von Müller; T Krenn; S Nemat; N Graf; A Simon
Journal:  Infection       Date:  2011-06-29       Impact factor: 3.553

2.  In vitro intracellular activity and in vivo efficacy of modithromycin, a novel bicyclolide, against Legionella pneumophila.

Authors:  Takafumi Sato; Kazuhiro Tateda; Soichiro Kimura; Yoshikazu Ishii; Keizo Yamaguchi
Journal:  Antimicrob Agents Chemother       Date:  2011-01-10       Impact factor: 5.191

Review 3.  Diagnosis and treatment of community-acquired pneumonia in adults: 2016 clinical practice guidelines by the Chinese Thoracic Society, Chinese Medical Association.

Authors:  Bin Cao; Yi Huang; Dan-Yang She; Qi-Jian Cheng; Hong Fan; Xin-Lun Tian; Jin-Fu Xu; Jing Zhang; Yu Chen; Ning Shen; Hui Wang; Mei Jiang; Xiang-Yan Zhang; Yi Shi; Bei He; Li-Xian He; You-Ning Liu; Jie-Ming Qu
Journal:  Clin Respir J       Date:  2017-09-26       Impact factor: 2.570

Review 4.  The atypical pneumonias: clinical diagnosis and importance.

Authors:  B A Cunha
Journal:  Clin Microbiol Infect       Date:  2006-05       Impact factor: 8.067

Review 5.  Legionnaires' disease: clinical differentiation from typical and other atypical pneumonias.

Authors:  Burke A Cunha
Journal:  Infect Dis Clin North Am       Date:  2010-03       Impact factor: 5.982

Review 6.  Legionnaires' Disease: Update on Diagnosis and Treatment.

Authors:  Diego Viasus; Valeria Gaia; Carolina Manzur-Barbur; Jordi Carratalà
Journal:  Infect Dis Ther       Date:  2022-05-03

7.  Legionnaires' Disease on the Rise in Switzerland: A Denominator-Based Analysis of National Diagnostic Data, 2007-2016.

Authors:  Fabienne B Fischer; Claudia Schmutz; Valeria Gaia; Daniel Mäusezahl
Journal:  Int J Environ Res Public Health       Date:  2020-10-08       Impact factor: 3.390

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.